

10/591614

AP20 Rec'd PCT/PTO 05 SEP 2006
PATENT APPLICATION

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of

Docket No: Q96727

Masakazu SATO, et al.

Appln. No.: National Stage of PCT/JP2005/003755

Confirmation No.: Not yet assigned

Group Art Unit: Not yet assigned

Filed: September 5, 2006

Examiner: Not yet assigned

For: THIAZOLE DERIVATIVE

INFORMATION DISCLOSURE STATEMENT
UNDER 37 C.F.R. §§ 1.97 and 1.98

MAIL STOP AMENDMENT

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

In accordance with the duty of disclosure under 37 C.F.R. § 1.56, Applicants hereby notify the U.S. Patent and Trademark Office of the documents which are listed on the attached PTO/SB/08 A & B (modified) form and/or listed herein and which the Examiner may deem material to patentability of the claims of the above-identified application.

One copy of each of the listed documents is submitted herewith, except for the following: U.S. patents and/or U.S. patent publications; and co-pending non-provisional U.S. applications filed after June 30, 2003.

The present Information Disclosure Statement is being filed: (1) No later than three months from the application's filing date; (2) Before the mailing date of the first Office Action on the merits (whichever is later); or (3) Before the mailing date of the first Office Action after filing a request for continued examination (RCE) under §1.114, and therefore, no Statement under 37 C.F.R. § 1.97(e) or fee under 37 C.F.R. § 1.17(p) is required.

In compliance with the concise explanation requirement under 37 C.F.R. § 1.98(a)(3) for foreign language documents, Applicants enclose herewith a copy of a Communication from a foreign patent office in a counterpart application citing such documents (International Search Report for PCT/JP2005/003755 dated June 14, 2006), together with an English-

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /T.S./

AP20 Rec'd PCT/PTO 05 SEP 2006

INFORMATION DISCLOSURE STATEMENT
U.S. Appln. No.: National Stage of PCT/JP2005/003755
Attorney Docket No. Q96727


language version (if not already included) of at least that portion of the Communication indicating the degree of relevance found by the foreign patent office. Also, an English-language abstract constitutes a concise statement of relevance for WO 03/080592.

In compliance with the concise explanation requirement under 37 C.F.R. § 1.98(a)(3) for foreign language documents, Applicants submits the following explanations: Japanese Patent / Publication Nos. 2001-163861 and 7-112975 are cited and discussed on page 4 of the present application. Additionally, English-language abstracts constitute concise statements of relevance for JP-A-2001-163861 and 7-112975.

The submission of the listed documents is not intended as an admission that any such document constitutes prior art against the claims of the present application. Applicants does not waive any right to take any action that would be appropriate to antedate or otherwise remove any listed document as a competent reference against the claims of the present application.

The USPTO is directed and authorized to charge all required fees, except for the Issue Fee and the Publication Fee, to Deposit Account No. 19-4880. Please also credit any overpayments to said Deposit Account.

Respectfully submitted,


Susan J. Mack
Registration No. 30,951

SUGHRUE MION, PLLC
Telephone: (202) 293-7060
Facsimile: (202) 293-7860

WASHINGTON OFFICE

23373

CUSTOMER NUMBER

Date: September 5, 2006

Substitute for Form 1449 A & B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(use as many sheets as necessary)</i>				Complete if Known	
				10/591614	
Application Number		National Stage of PCT/JP2005/003755			
Confirmation Number		Not yet assigned			
Filing Date		September 5, 2006			
First Named Inventor		Masakazu SATO et al.			
Art Unit		Not yet assigned			
Examiner Name		Not yet assigned			
Attorney Docket Number		Q96727			
Sheet	1	of	1		

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	Document Number		Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document
		Number	Kind Code ² (if known)		
		US 6,770,663	B2	08-03-2004	Wagle et al.
		US			
		US			

FOREIGN PATENT DOCUMENTS							
Examiner Initials*	Cite No. ¹	Foreign Patent Document			Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Translation ⁶
		Country Code ³	Number ⁴	Kind Code ⁵ (if known)			
		JP	2003-524010	A	08-12-2003	SMITHKLINE BEECHAM PLC	Abstract
		WO	01/62756	A1	08-30-2001	SMITHKLINE BEECHAM PLC	
		WO	03/087304	A2	10-23-2003	BIOGEN, INC.	
		WO	03/042207	A1	05-22-2003	SMITHKLINE BEECHAM CORP.	
		WO	02/076494	A2	10-03-2002	MICHAEL PAULISTA et al.	
		WO	03/080592	A1	10-02-2003	JUNYA TAKAHASHI et al.	Abstract
		WO	00/61576	A1	10-19-2000	SMITHKLINE BEECHAM CORP.	
		WO	01/72737	A1	10-04-2001	SMITHKLINE BEECHAM CORP.	
		WO	01/62756	A1	08-30-2001	SMITHKLINE BEECHAM CORP.	
		WO	02/40468	A	05-23-2002	SMITHKLINE BEECHAM CORP.	
		WO	99/03837	A1	01-28-1999	ORTO-MCNEIL PHARMACEUTICAL, INC.	
		WO	96/03387	A1	02-08-1996	G.D. SEARLE & CO.	
		WO	03/062215	A1	07-31-2003	KYLIX PHARMACEUTICALS B.V.	
		WO	01/85723	A1	11-15-2001	JAMES BLACK FOUNDATION LTD.	
		WO	01/44203	A1	06-21-2001	THE PROCTER & GAMBLE COMPANY	
		WO	2004/005264	A2	01-15-2004	AXXIMA PHARMACEUTICALS AG	
		JP	2001-163861	A	06-19-2001	NIPPON SODA CO.	Abstract
		JP	7-112975	A	05-02-1995	SHIONOGI & CO. LTD.	Abstract

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city, and/or country where published.	Translation ⁶
		TSUTOMU SOMA et al., « Analysis of Apoptotic Cell Death in Human Hair Follicles <i>In Vivo and In Vitro</i> », The Journal of Investigative Dermatology Inc., APOPTOSIS IN HUMAN HAIR, Vol. 111, No. 6, pp. 948-954, (December 1998)»	
		KERSTIN FOITZIK et al., "Control of murine hair follicle regression (catagen) by TGF-β1 <i>in vivo</i> ", The FASEB Journal, Vol. 14, pp. 752-760, (April 2000)	

Examiner Signature	/Taofiq Solola/	Date Considered	10/19/2009
--------------------	-----------------	-----------------	------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² See Kind Codes of USPTO Patent Documents at www.uspto.gov, MPEP 901.04 or follow the hyperlink from the title of the document to the intranet. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST. 3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to indicate here if English language translation is attached.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /T.S./
(Page 1 of 1)